4.7 Article

A flux-adaptable pump-free microfluidics-based self-contained platform for multiplex cancer biomarker detection

Journal

LAB ON A CHIP
Volume 21, Issue 1, Pages 143-153

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/d0lc00944j

Keywords

-

Funding

  1. National Key Research and Development Program of China [2016YFD0500604, 2016YFD0500603]
  2. National Natural Science Foundation of China [61775140]
  3. Shanghai Science and Technology Commission [18142200800]
  4. Shanghai Rising-Star Program [20QA1407000]

Ask authors/readers for more resources

Microfluidics plays a crucial role in advancing portable and cost-effective bioanalytical diagnostics. A pump-free microfluidic chip has been developed for rapid and sensitive detection of multiple biomarkers, offering potential applications in disease monitoring.
Microfluidics drives technological advancement in point-of-care (POC) bioanalytical diagnostics towards portability, fast response and low cost. In most microfluidic bioanalytical applications, flowing antigen/antibody reacts with immobilized antibody/antigen at a constant flux; it is difficult to reach a compromise to simultaneously realize sufficient time for the antigen-antibody interaction and short time for the entire assay. Here, we present a pump-free microfluidic chip, in which flow is self-initialized by capillary pumping and continued by imbibition of a filter paper. Microfluidic units in teardrop shape ensure that flow passes through the reaction areas at a reduced flux to facilitate the association between antigen and antibody and speeds up after the reaction areas. By spotting different antibodies into the reaction area, four types of biomarkers can be measured simultaneously in one microfluidic chip. Moreover, a small-sized instrument was developed for chemiluminescence detection and signal analysis. The system was validated by testing four biomarkers of colorectal cancer using plasma samples from patients. The assay took about 20 minutes. The limit of detection is 0.89 ng mL(-1), 1.72 ng mL(-1), 3.62 U mL(-1) and 1.05 U mL(-1) for the assays of carcinoembryonic antigen, alpha-fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9, respectively. This flux-adaptable and self-contained microfluidic platform is expected to be useful in various POC disease-monitoring applications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available